In addition to Abs with ADCC activity, the vaccine used in the RV144 trial induced anti-HIV gp120-specific Abs able to activate the complement cascade and bind to Fc-receptors on monocytes to induce AD cellular phagocytosis (ADCP) and AD cellular trogocytosis (ADCT) (41, 42). Here, DDX41 is linked to Alzheimer disease.